What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Lung cancer, Oncology, Chemotherapy and Surgery.
Internal medicine is frequently linked to Gastroenterology in his study.
His Lung cancer research is multidisciplinary, relying on both Cancer, Epidermal growth factor receptor and Disease.
The study incorporates disciplines such as Clinical endpoint and Adenocarcinoma in addition to Oncology.
His Chemotherapy study incorporates themes from Survival rate and Atezolizumab.
His Surgery research includes elements of Erlotinib Hydrochloride, Erlotinib and Clinical trial.
His most cited work include:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (6022 citations)
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (3639 citations)
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
What are the main themes of his work throughout his whole career to date?
Tony Mok mainly focuses on Internal medicine, Oncology, Lung cancer, Chemotherapy and Cancer research.
In his research, Gastroenterology is intimately related to Surgery, which falls under the overarching field of Internal medicine.
His Oncology research focuses on subjects like Carboplatin, which are linked to Paclitaxel and Atezolizumab.
Tony Mok focuses mostly in the field of Lung cancer, narrowing it down to matters related to Cancer and, in some cases, Pathology.
The concepts of his Chemotherapy study are interwoven with issues in Regimen and Crizotinib.
His biological study spans a wide range of topics, including Carcinogenesis, Cell growth and Exon.
He most often published in these fields:
- Internal medicine (68.38%)
- Oncology (56.19%)
- Lung cancer (42.10%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (68.38%)
- Oncology (56.19%)
- Lung cancer (42.10%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy.
Internal medicine is a component of his Hazard ratio, Atezolizumab, Carboplatin, Cancer and Clinical endpoint studies.
His research in Oncology intersects with topics in Pembrolizumab and Phases of clinical research.
His Lung cancer study combines topics in areas such as Randomized controlled trial and Epidermal growth factor receptor.
His Cancer research research is multidisciplinary, incorporating elements of Mutant, Immune system, non-small cell lung cancer, Carcinoma and ROS1.
His Chemotherapy research includes themes of Gastroenterology, Nivolumab and Discontinuation.
Between 2017 and 2021, his most popular works were:
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer (804 citations)
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (753 citations)
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. (391 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Tony Mok mostly deals with Internal medicine, Oncology, Lung cancer, Hazard ratio and Chemotherapy.
His studies in Oncology integrate themes in fields like Clinical trial and Confidence interval.
His Lung cancer study combines topics from a wide range of disciplines, such as Phases of clinical research, Carcinoma and Epidermal growth factor receptor.
His work carried out in the field of Hazard ratio brings together such families of science as Gastroenterology and Performance status.
Many of his research projects under Chemotherapy are closely connected to Response Evaluation Criteria in Solid Tumors with Response Evaluation Criteria in Solid Tumors, tying the diverse disciplines of science together.
Tony Mok combines subjects such as T790M and Pemetrexed with his study of Osimertinib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
